May 29, 2017 at 01:07AM
from
Featured Post
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA)
Twenty Practical Steps to Better Corporate Governance | The Corporate Secretaries International Association (CSIA) Please click the li...
Showing posts with label 2017 at 01:12AM. Show all posts
Showing posts with label 2017 at 01:12AM. Show all posts
Monday, May 29, 2017
‘It’s very possible these sources don’t exist’: Trump accuses reporters of making up anonymous sources
Monday, May 22, 2017
Twitter Founder Apologizes for Giving President Trump a Platform: ‘It’s a Very Bad Thing’
May 22, 2017 at 01:12AM
from
A ‘paradigm shift’ is taking place in financial technology
A “paradigm shift” is taking place in financial technology.
Venture capital firms, which poured $117 billion into fintech startups from 2012 to 2016, have been pulling back on their investments. Meanwhile, established financial firms are positioned to step up their spending.
In a big note out to clients on May 18 titled “Fintech: A Gauntlet to Riches,” a group of equity analysts at Morgan Stanley said this shift will lead to an environment where legacy firms, or incumbents, “take the reigns”of financial innovation.
“Financials and payments incumbents are likely to be emboldened to step up R&D and take the investment lead, and this combination of VC/incumbent behavior represents a paradigm shift that should benefit incumbents’ [return on investment],” Morgan Stanley said.
The role of VCs will continue to diminish
Financial technology companies experienced a surge in funding from 2012 to 2015, during which time venture capital firms poured $92 billion into the space. Now it looks like those VC firms are experiencing a bit of a hangover.
In 2016, global venture capital investment in fintech companies dipped to $25 billion, from $47 billion in 2015.
“Big firms just sort of piled on a bunch of, let’s say, happy money,” Firms were thinking, we have money, we have capital, we have to spend it,” she said.
This environment of “happy money” sent valuations for fintechs to levels that some investors view as unreasonably high. For instance, Andy Stewart, a managing partner at Motive Partners, said at the International Fintech conference in London that valuations in fintech were “frothy,” or not connected to performance.
“Pullback in fintech investment over the past year is indicative of a realization of lower [return on investments] than initially hoped due to some unique challenges to disrupting in the financials industry, and our suspicion is that VC investors will continue to scale back investing,” Morgan Stanley said.
Incumbents may fill the void
According to Morgan Stanley, there are a number of factors that will push legacy financial firms to step up their investments in fintech companies. The most obvious factor is the fear of disruption.
“[T]he threat of disruption from fintechs is forcing incumbents to up their investments in technology to gain operating efficiencies and preserve market share,” the bank said.
Deregulation is another trigger. If the Trump administration follows through on its promises of Wall Street deregulation, then incumbent firms won’t have to spend as much cash on regulatory compliance. That would free up money for fintech investment initiatives. Legacy firms’ focus on lowering cost also provides an incentive to invest in fintech.
“Managing expenses remains a key focus for incumbents as one of the drivers for earnings growth,” the bank said.”It follows that there is an increasing trend towards implementing more technology to drive efficiencies with moderated headcount growth going forward.”
What is the net outcome of this shift? A better business landscape for well-established Wall Street firms.
“As incumbents pick up investment while VCs reduce investment, we tilt towards a world where incumbents are less susceptible to disintermediation and more likely to co-opt new technologies,” the bank said.
Join the conversation about this story »
NOW WATCH: Trump is reportedly selling his Caribbean estate for $28 million — take a look inside
May 22, 2017 at 01:08AM
from Frank Chaparro
Wednesday, May 17, 2017
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
Biogen Inc.BIIB announced the acquisition of New York-based private pharma company Remedy Pharmaceuticals’ phase III candidate, Cirara for an upfront payment of $120 million. Cirara is being evaluated for the treatment of large hemispheric stroke (LHI).
Shares were up almost 1.5% on Monday in response to the news. However, this year, Biogen’s shares have declined 8.9% so far, while the Zacks classified Biomed-Genetics industry recorded an increase of 1.3%.
LHI is a severe kind of ischemic stroke where cerebral edema often leads to stroke-related death. In proof-of-concept studies, Cirara has shown the potential to reduce brain swelling, disability and the death risks in patients with LHI. Incidentally, Cirara enjoys Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke.
Per the terms of the deal, Remedy will share the development cost of Cirara and will also be entitled to potential milestone and royalty payments.
The acquisition is in sync with Biogen’s efforts to diversify its pipeline beyond the multiple sclerosis market tothe neuroscience/neurologic diseases area.
The company holds a strong position in MS market with a wide range of products. However as competition intensifies there, Biogen tries to diversify its pipeline and aims to be a leader in the neuroscience/neurologic diseases area.
Biogen is looking to strengthen its Alzheimer’s disease (AD) and other neurodegenerative disorders pipeline. Biogen’s AD pipeline comprises candidates with different mechanisms of action including anti-tau (BMS-986168) and anti-amyloid (aducanumab) candidates as well as a BACE inhibitor (elenbecestat) program. We remind investors that Biogen licensed the anti-tau candidateBMS-986168from Bristol-Myers Squibb Company BMY, per a deal announced last month.
The Dec 2016 FDA approval of Biogen and partner Ionis Pharmaceuticals, Inc.’s IONS spinal muscular atrophy (SMA) treatment, Spinraza (nusinersen), consolidated its position in the neurological disease market with the drug being the first and only treatment to be approved in the U.S. for SMA.
The acquisition of Cirara complements Biogen’s ongoing development efforts in stroke. Biogen has another drug in development, called natalizumab which is being evaluated in a phase IIb study to improve its functional outcomes by limiting brain inflammation after strokes.
Biogen carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharmaceutical sector is Akari Therapeutics, Plc AKTX with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Shares of Akari Therapeutics have risen 28.4% this year so far.
5 Trades Could Profit “Big-League” from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington’s changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report
Akari Therapeutics PLC (AKTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
May 17, 2017 at 01:02AM
from Zacks Equity Research
Visa (V) Hits 52-Week High on Strong Results, Recent Deals
On May 15, the stock of Visa Inc. V hit a 52-week high of $93.42. The rise in the stock is believed to have been driven by strong fiscal second-quarter results as well as the signing up of recent deals and renewal agreements.
Over the past year, the stock has returned 21.7%, outperforming the 18.6% gain of the Zacks categorized Financial Transaction Services industry and 17% gain of the S&P 500 index.
The company’s earnings of 86 cents per share, beat the Zacks Consensus Estimate by 8.9% and also improved 27% year over year. Net operating revenue of $4.5 billion surpassed the Zacks Consensus Estimate of $4.2 billion and revenues climbed 23% year over year. This upside was primarily driven by the acquisition of Visa Europe and consistent growth in cross-border volume and processed transactions.
The results reflected broad-based growth with solid payment volume growth, a double-digit increase in cross-border revenue and healthy operating metrics from all the regions.
Investors also favorably view a number of deal wins and renewals that drive transaction volume growth. In North America, Visa renewed a multi-year credit, debit, commercial and prepaid partnership with PNC Financial Services Group. It also renewed a multi-year debit agreement with Citizens Bank and multi-year credit and debit agreements with First National Bank of Omaha.
On the co-brand side, Visa renewed an important credit card relationship of Hyatt Hotels and Resorts. In Asia Pacific, Visa signed a 10-year exclusive partnership with ANZ Bank. In both Australia and New Zealand, it also signed a commercial credit partnership with Citibank covering multiple markets in Asia Pacific.
In Taiwan, Visa signed a multi-year credit and debit agreement with CTBC Bank Taiwan. In its Latin America region, Banco Popular de Puerto Rico, the largest bank in credit card issuer in Puerto Rico renewed a multi-year credit and debit partnership. In Europe, Visa signed a PAN-Nordic debit renewal with Nordea Bank and a commercial and consumer card renewal with BNP Paribas Group in France.
In addition to these renewals, Visa signed a number of key partnerships. It announced the IBM Watson partnership to help support payments in the Internet of Things and encourage the usage of tokenization.
Visa also executed the PayPal partnership in Asia Pacific, which is an extension of its partnership in the United States. This partnership will assertain transaction data sharing and offer enhanced consumer experience.
Recently, Visa announced the launch of an enhanced transaction data capability for Amazon business customers in the United States. This enables participating issuers to provide their U.S. commercial account holders a comprehensive view of their Amazon business purchases including full-line item details on purchases made with their Visa commercial card that integrates with popular reconciliation tools.
Investors are also impressed with the company’s digital expansion efforts that made great progress in fiscal second quarter. Visa Checkout has seen tremendous growth and now provides services to more than 20 million enrolled accounts.
Additional brand merchants are adopting Visa Checkout to improve their online shopping experience. And the growing list of over 300,000 merchants now includes Alaska Airlines, Avis, Marriott and Walmart, among others.
Visa carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Some other players from the space with the same Zacks Rank are Total System Services Inc. TSS, Vantiv, Inc. VNTV, and Financial Engines, Inc. FNGN. The bottom line at Total System, Vantiv and Financial Engines beat their estimates by 8.22%, 3.28% and 8.7%, respectively.
5 Trades Could Profit “Big-League” from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington’s changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates and spending surges in defense and infrastructure. See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Financial Engines, Inc. (FNGN): Free Stock Analysis Report
Visa Inc. (V): Free Stock Analysis Report
Total System Services, Inc. (TSS): Free Stock Analysis Report
Vantiv, Inc. (VNTV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
May 17, 2017 at 01:02AM
from Zacks Equity Research
Can Consumer Staples Overcome Headwinds?
Despite rising consumer spending and moderate improvement in U.S. economic growth, the consumer staples sector doesn’t seem to be the perfect choice for investors right now; it is viewed as more attractive when macro-economic environment remains sluggish. The bullish growth in 2017 will also invite another Fed rate hike. Higher U.S. interest rates will likely lead to a stronger dollar, which would hurt overseas profits and create an unfavorable environment for emerging economies.
Other headwinds like potential price wars, a competitive environment and slowdown in international markets may also hinder growth. Also, investors remain skeptical whether policies promised by the Trump administration will take shape.
We note that in spite of benefiting from lower fuel prices and higher wages, consumers are reluctant to spend more. The Consumers’ outlook for the labor market was also less favorable in April.
Hence, investors should carefully select stocks for their portfolio as certain headwinds are likely to prevail in the coming months.
WEAKNESSES
Pressurized Margins
The grocery/supermarket business has been grappling with food deflation, stiff competition, aggressive promotional environment, and waning store traffic over the past few quarters. These headwinds have severely impacted major food grocers like The Kroger Co. (KR), Whole Foods Market, Inc. (WFM), SuperValu, Inc. (SVU), Sprouts Farmers Market (SFM) and United Natural Foods, Inc. (UNFI). An oversupply in some types of food – particularly meat, poultry and dairy –dragged prices lower and compelled grocery stores to do more aggressive promotions.
Meanwhile, we note that the trend is finally beginning to shift toward inflation. Meat prices are abating and dairy prices have started to rise. This is expected to result in an increase in commodity prices, thereby putting pressure on margins. Also, price wars between companies may erode profits and margins in the near term.
Slowdown in Emerging Markets
The majority of the global population lives in emerging economies. Due to a slowdown in income and consumption growth, affordability is low. Though there remains a huge opportunity for sales growth in these markets, currently the state of affairs remains volatile.
Aside from China, which is struggling the past few quarters, developing countries like Brazil and Mexico are facing economic slowdowns. The Middle East, Russia and Ukraine are witnessing continued political and civil unrest, resulting in challenging operating conditions. Some developed markets are also facing weakness due to sluggish consumer demand.
For example, consumer product company Unilever plc (UL) still sees declining volumes in Brazil, while performance has improved in China and India. The company is also witnessing weakness in the developed markets with little sign of recovery in North America or Europe. Moreover, it remains cautious as consumer demand continues to be weak.
Beverage giant The Coca-Cola Company (KO) also remains apprehensive of broader economic challenges in future quarters. While the macro environment is improving in North America, Japan and India, Coca-Cola expects challenges in many key emerging/developing markets like Brazil, Russia and China.
Companies like Procter & Gamble Co. (PG) and Kellogg Co. (K) are also struggling with decelerating growth in the developing markets and currency headwinds. U.K.-based brewer Diageo Plc (DEO) also faces macroeconomic headwinds and tough retail conditions in emerging markets.
Higher Operating Expenses to Limit Profits
Consumer staple companies tend to spend heavily on marketing and advertising. Though advertising strengthens brand appeal and helps to counter competition, it severely hits the profit margins of these companies. Companies like Kimberly-Clark Corp. (KMB), PepsiCo Inc. (PEP) and Procter & Gamble have significantly stepped up their investments in marketing, innovation, R&D, supply chain and capacity additions, which will weigh on profits in the short term. Pinnacle Foods, Inc. (PF) incurs higher expenses as a result of innovation and promotional activity.
Increased Competition
Consumer staples companies are also hit by stiff competition, which results in lower pricing power and a decline in market share. This in turn compresses margins and earnings. For example, Kimberly-Clark’s diaper segment is witnessing lower market share and higher competitive promotional activity, as its Huggies diapers are competing with Procter & Gamble’s cheaper Luvs and upscale Pampers offerings. The J.M. Smucker Co.’s (SJM) mainstream Pet Food business is also facing heightened competitive activity and challenges in dry dog food amid a deflationary macro environment, which is impacting the performance of its Kibbles ‘n Bits brand.
Unfavorable Foreign Currency Impact
Companies with a significant presence in emerging markets are being affected by currency headwinds, given the weakening of many emerging market currencies against the U.S. dollar.
Foreign exchange is a major headwind for companies like Estee Lauder Companies, Inc. (EL), Mondelez International, Inc. (MDLZ), Unilever and PepsiCo, which have significant business outside the U.S. Venezuelan currency issues are also hurting Nu Skin Enterprises, Inc.’s (NUS) earnings significantly.
Declining Volumes
Many consumer staples companies are struggling with declining volume or soft volume growth, which is hurting their top line.
For example, tobacco companies like Altria Group, Inc.(MO), Philip Morris International, Inc. (PM) and Reynolds American, Inc. (RAI) are facing declining shipment volumes, mainly due to anti-tobacco campaigns and general shifting from cigarettes and cigars to alternative tobacco products such chewable nicotine, e-cigarettes, etc. The government has imposed higher excise taxes on cigarettes, as a result of which tobacco companies are increasing prices. Further, rising competition from fake versions of branded cigarettes by local retailers is also hurting cigarette volumes.
Volumes of food company Mondelez International have been hurt by the elasticity impact from higher pricing and category weakness because of soft consumer demand.
Beverage companies like Dr. Pepper Snapple Group Inc. (DPS), Coca-Cola and PepsiCo have also been seeing declining volume trends in their carbonated soft drinks businesses due to category weakness. A muted volume trend will remain a concern going forward.
Bottom Line
As is evident, there are plenty of concerns in the consumer staples industry. However, as regards investing in the space right now, are there any opportunities for short-term investors?
Check out our latest Consumer Staples Outlook for more on the current state of affairs in this market from an earnings perspective and the trend in this important sector of the economy.
Zacks’ Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks’ private buys and sells in real time from value to momentum… from stocks under $10 to ETF to option movers… from insider trades to companies that are about to report positive earnings surprises (we’ve called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks’ secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Whole Foods Market, Inc. (WFM): Free Stock Analysis Report
United Natural Foods, Inc. (UNFI): Free Stock Analysis Report
Unilever PLC (UL): Free Stock Analysis Report
SuperValu Inc. (SVU): Free Stock Analysis Report
J.M. Smucker Company (The) (SJM): Free Stock Analysis Report
Sprouts Farmers Market, Inc. (SFM): Free Stock Analysis Report
Reynolds American Inc (RAI): Free Stock Analysis Report
Philip Morris International Inc (PM): Free Stock Analysis Report
Procter & Gamble Company (The) (PG): Free Stock Analysis Report
Pinnacle Foods, Inc. (PF): Free Stock Analysis Report
Pepsico, Inc. (PEP): Free Stock Analysis Report
Nu Skin Enterprises, Inc. (NUS): Free Stock Analysis Report
Altria Group (MO): Free Stock Analysis Report
Mondelez International, Inc. (MDLZ): Free Stock Analysis Report
Kroger Company (The) (KR): Free Stock Analysis Report
Coca-Cola Company (The) (KO): Free Stock Analysis Report
Kimberly-Clark Corporation (KMB): Free Stock Analysis Report
Kellogg Company (K): Free Stock Analysis Report
Estee Lauder Companies, Inc. (The) (EL): Free Stock Analysis Report
Dr Pepper Snapple Group, Inc (DPS): Free Stock Analysis Report
Diageo PLC (DEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
May 17, 2017 at 01:02AM
from Zacks Equity Research
Analyst Reports for Abbott, EOG, General Dynamics & Others
Tuesday May 16, 2017
Today’s Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), EOG Resources (EOG) and Abbott (ABT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>
General Dynamics’ shares have gained +34.6% over the last one year, outperforming the Zacks Aerospace – Defense industry, which increased +20.8% over the same period. The Zacks analyst likes the improved outlook for the company’s broad portfolio of products and services given the administration’s plans for material spending increases. The expectation is for solid growth momentum post 2017, following the introduction of G500 in 2018, major revenue recognition from Combat Systems’ huge backlog and the Ohio-class Replacement (ORP) submarine program, which should add substantially to the top line by 2019. On the flip side, any slip up in the Trump administration’s commitment to raise defense spending remains a headwind for this company as well as many of its peers. Valuation has become an issue as well following the stock’s aforementioned run up. (You can read the full research report on General Dynamics here >>>)
EOG Resources shares have gained around +16.1% over the last one year, outperforming the Zacks Oil & Gas E&P Industry, which has lost -9.3% over the same period. The Zacks analyst likes the fact that EOG Resources has premium acreages in three prospective oil plays in the U.S like Permian, Bakken and Eagle Ford shale plays. The company has also decided to complete more wells in 2017, which should contribute to production growth. However, significantly higher exploration expenses incurred during the first three months of this year is cause for concern even though Q1 results were better than expected on the back of volume gains and improved realizations. (You can read the full research report on EOG Resources here >>>)
Abbott shares have outperformed the Zacks Medical sector in the year-to-date period (the stock is up +14% vs. +7.7% gain for the sector) on the back of greater appreciation for the company’s strategic repositioning through acquisitions/divestitures. The St. Jude Medical buyout will complement its cardiovascular devices business. Also, the company’s plans to focus on selling its portfolio in core therapeutic areas. Meanwhile, weakness in the nutrition business in China and sluggish growth in the Venezuelan market is a concern. (You can read the full research report on Abbott here >>>)
Other noteworthy reports we are featuring today include Marriott (MAR), Northrop Grumman (NOC) and Symantec (SYMC).
Will You Make a Fortune on the Shift to Electric Cars?
Here’s another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It’s not the one you think.
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
Today’s Must Read
Featured Reports
Northrop Grumman (NOC) Tops Q1 Earnings, Sales, Hikes View
Te Zacks analyst thinks solid year over year growth boosted Northrop’s better-than-expected Q1 results.
Edison International (EIX) Beats on Q1 Earnings, Up Y/Y
The covering analyst thinks Edison International’s better-than-expected earnings were driven by the favorable performance in Southern California Edison.
GoDaddy (GDDY) Beats Q1 Earnings & Revenues
With GoDaddy delivering strong Q1 results, the Zacks analyst believes that its strategic acquisitions and international expansion are positives.
BorgWarner (BWA) Tops on Earnings and Revenue Estimates
The covering analyst thinks BorgWarner it will benefit from global expansion, capital deployment and restructuring initiatives.
AGCO (AGCO) Tops Estimates in Q1, Lifts ’17 Sales Outlook
The Zacks analyst thinks AGCO will gain from increased investments. Focus on capital allocation plan, new product development and cost-reduction efforts will also drive growth.
Agilent Technologies (A) Rides High On Broad-based portfolio
The covering analyst believes that Agilent’s focus on life sciences, genomics, diagnostics and wireless test markets offer higher growth potential.
Universal Health (UHS) Tops Q1 Earnings on Higher Revenues
The Zacks analyst views favorably Universal Health’s earnings outperformance which is largely supported by the company’s consistent revenue increase, robust inorganic growth and solid fundamentals.
New Upgrades
Puma (PBYI) Posts Q1 Loss; Neratinib Progressing Well
Puma’s lead cancer candidate, neratinib, looks promising with several studies underway. Approval will be a huge boost for the company, believes the Zacks analyst.
TiVo (TIVO) Q1 Revenues Benefited from New Deals & Products
The Zacks analyst thinks that the higher number of distribution deals and merger with Rovi will support TiVo’s expansion plans and strengthen its customer base and in turn continue to boost revenues.
Marriott (MAR) Poised for Growth Post Solid Q1 Earnings
The covering analyst remains upbeat about Marriott post earnings. Despite risks, Marriott is poised to grow given the Starwood acquisition, rise in demand for travel and huge international exposure.
New Downgrades
Strayer (STRA) Q1 Earnings Meet, Revenue Per Student Declines
Strayer Education’s earnings were in line with analysts’ expectations. The covering analyst stresses that tuition cuts and unfavorable mix of students is resulting in lower revenue per student.
Slow Digital Camera Sales, Restructuring Hurt Nikon (NINOY)
Nikon reported a net loss in fiscal 2017, compared to earnings posted last fiscal. Its bottom line remains vulnerable to restructuring expenses, currency risks and a shrinking digital camera market.
Symantec’s (SYMC) Q4 Results Disappoints; Guidance Weak
A dismal 4Q17 result along with soft guidance for the forthcoming quarter and FY18 makes the Zacks analyst increasingly cautious about its near-term performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Symantec Corporation (SYMC): Free Stock Analysis Report
Northrop Grumman Corporation (NOC): Free Stock Analysis Report
Marriott International (MAR): Free Stock Analysis Report
General Dynamics Corporation (GD): Free Stock Analysis Report
EOG Resources, Inc. (EOG): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
May 17, 2017 at 01:02AM
from Sheraz Mian
Saturday, May 13, 2017
Rebecca Hoffman retweeted: VIDEO: Who’s the Client? Not the CEO, @Abercrombie’s Bostrom Says http://ift.tt/2qAmjC0 #corpgov #compliance
|
|
Rebecca Hoffman retweeted:
VIDEO: Who’s the Client? Not the CEO, @Abercrombie‘s Bostrom Says http://ift.tt/2qAmjC0 #corpgov #compliance
May 13, 2017 at 01:08AM
https://twitter.com/RebeccaEHoffman/status/863119849815498752
from Rebecca Hoffman
Kerstin retweeted: #CorpGov $ENRT going #viral? @Brettfoster82 by #TkTCUJ5VtuNb8cU by #OFc3KKwcDorAKxI by… by #vnvep88w844tJNH
|
|
Kerstin retweeted:
#CorpGov $ENRT going #viral? @Brettfoster82 by #TkTCUJ5VtuNb8cU by #OFc3KKwcDorAKxI by… by #vnvep88w844tJNH
May 13, 2017 at 01:08AM
https://twitter.com/bobrov_androp/status/863119279763447810
from Kerstin
Monday, May 8, 2017
Appeal for quotas to get women on boards – The West Australian
The West Australian |
Appeal for quotas to get women on boards
The West Australian Diane Smith-Gander says we’ve got to increase female workforce participation. Picture: Sharon Smith/The West Australian. One of WA’s highest-profile business leaders wants gender diversity quotas on company boards unless more women are appointed … |
May 08, 2017 at 12:34AM
from
Friday, April 28, 2017
Trump Tax Plan Poses No Threat to Credit Unions—Yet
Credit union leaders are keeping an eye on the possible impacts of Trump’s tax proposal.
April 28, 2017 at 01:11AM
from
Monday, April 24, 2017
Macron vs. Le Pen looks evident on real votes – EUR/USD shooting higher
Two hours after voting has closed and the projections first leaked by the Belgian press and then by exit polls looks real. The run-off on May 7th will see centrist Emmanuel Macron vs. extreme-right Marine Le Pen. EUR/USD was shooting higher in very early trading above 1.09. Now we already have more trading desks open, and the pair continues […]
The post Macron vs. Le Pen looks evident on real votes – EUR/USD shooting higher appeared first on Forex Crunch.
April 24, 2017 at 01:07AM
from Yohay Elam
Subscribe to:
Posts (Atom)